North America Hemoglobinopathies Market Report and Forecast 2024-2032

North America Hemoglobinopathies Market Outlook

North America hemoglobinopathies market size is expected to grow at a CAGR of 5.10% during the forecast period of 2024-2032, driven by the growing prevalence of sickle cell anemia and thalassemia along with the rising advancements in treatment and diagnostics in the region.

Key Takeaways

• In the United States, around 100,000 individuals are affected by sickle cell disease. It is highly prevalent in African Americans, affecting 1 out of every 365 African American births.

• In December 2023, the FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, to treat sickle cell disease (SCD) in patients aged 12 years and more.

• In July 2023, the National Institutes of Health awarded a USD 2.6 million grant to a Rice University research team to investigate the efficacy and safety of gene editing technology to treat sickle cell disease.

North America Hemoglobinopathies Market Analysis

Hemoglobinopathies are a group of inherited disorders characterized by the abnormal structure or production of the hemoglobin molecule. Sickle cell anemia and thalassemia are some common types of hemoglobinopathies. In the United States, around 100,000 individuals are affected by sickle cell disease. It is highly prevalent in African Americans, occurring in 1 out of every 365 African American births. The rising prevalence of sickle cell anemia disease is expected to increase demand for effective treatment options, driving North America hemoglobinopathies market growth.

One of the major market trends is the development of novel therapies to combat the growing cases of hemoglobinopathies. Furthermore, the rise in regulatory approvals by health regulatory bodies including United States Food and Drug Administration (FDA) to address the unmet of clinical needs of a large patient base is likely to boost market size in the region. In December 2023, the FDA granted approval to the first cell-based gene therapies, Casgevy and Lyfgenia, to treat sickle cell disease (SCD) in patients aged 12 years and more. Such innovations along with their high acceptance rate is projected to augment the North America hemoglobinopathies market share in the forecast period.

Casgevy, developed by Vertex Pharmaceuticals Incorporated, and a Swiss–American biotechnology CRISPR Therapeutics AG, is the first FDA-approved CRISPR/Cas9 therapy for the treatment of sickle cell disease in patients with recurrent vaso-occlusive crises. On the other hand, Bluebird Bio, Inc.’s Lyfgenia is a cell-based gene therapy that utilizes a lentiviral vector for gene delivery. It is used for the treatment of sickle cell disease in patients showing a history of vaso-occlusive events. The approval of these novel gene therapies which have the potential to cure the inherited disease is anticipated to fuel the North America hemoglobinopathies market demand.

The market is also driven by increased investments from both government and private sectors to support research activities aimed at the advancement of diagnostic methods and treatment of hemoglobinopathies. For instance, in July 2023, the National Institutes of Health awarded a USD 2.6 million grant to a Rice University bioengineer and his research team. The 4-year grant was intended to be used in investigating the efficacy and safety of gene editing technology to treat sickle cell disease. The rise in funding will help in the development of new treatment therapies which will propel the market growth in the region.

North America Hemoglobinopathies Market Segmentation

The report offers a detailed analysis of the market based on the following segments:

North America Hemoglobinopathies Market: Competitor Landscape

The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Sangamo Therapeutics, Inc.

• Global Blood Therapeutics

• Bluebird bio, Inc.

• Emmaus Life Science Inc.

• Pfizer, Inc.

• Novartis AG

• Prolong Pharmaceuticals, LLC

• Bioverativ Inc.

• Gamida Cell

• Celgene Corporation

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

North America Hemoglobinopathies Market Report Snapshots

North America Hemoglobinopathies Market Size

North America Hemoglobinopathies Market Analysis

North America Hemoglobinopathies Companies